- Stay Connected
Onyx finishes FDA submission for blood cancer drug – BusinessWeek
Onyx finishes FDA submission for blood cancer drug BusinessWeek The South San Francisco, Calif., company has been submitting material to the FDA since January after the drug, called carfilzomib, received a "Fast Track" designation from the agency. That helps speed up the review of drugs that aim to treat serious or … Onyx files FDA application for quick drug review Onyx Turns in FDA Application for Second Cancer Drug Beacon BreakingNews – Onyx Submits Carfilzomib For FDA Approval |
